Genentech Overview
- Founded
-
1976
- Status
-
Acquired/Merged
- Employees
-
20,259
- Latest Deal Type
-
Grant
- Latest Deal Amount
-
$256K
Genentech General Information
Description
Manufacturer of pharmaceutical products intended to focus on immunology and oncology medical fields. The company offers pharmaceutical products that have applications in ophthalmology, metabolism and virology fields, thereby enabling its patients to avail the treatment of life-threatening diseases for living a healthier life.
Contact Information
Website
www.gene.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Office
- 1 DNA Way
- South San Francisco, CA 94080
- United States
+1 (650) 000-0000
Genentech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Grant | 01-Sep-2020 | $256K | Completed | Generating Revenue | ||
| 6. Secondary Transaction - Private | 12-Mar-2009 | 000.00 | 00000 | Completed | Generating Revenue | |
| 5. 2PO | 20-Jul-1999 | Completed | Generating Revenue | |||
| 4. Merger/Acquisition | 17-Jun-1999 | 00.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 3. IPO | 14-Oct-1980 | 0000 | 000.00 | Completed | Generating Revenue | |
| 2. Early Stage VC | 17-Oct-1979 | $10M | $10.2M | Completed | Generating Revenue | |
| 1. Early Stage VC | 01-Jan-1976 | $200K | $200K | Completed | Generating Revenue |
Genentech Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Manufacturer of pharmaceutical products intended to focus on immunology and oncology medical fields. The company offers
Biotechnology
South San Francisco, CA
20,259
As of 2022
000.00
0000000000
000000
adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliq
0000 000000000
Boston, MA
0000
As of 0000
00.00
0000-00-00
000000&0
000000
velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupid
0000 000000000
Bothell, WA
0000
As of 0000
00.000
000
0000-00-00
000000&0
00.000
Add Comparison
Genentech Competitors (19)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alexion | Formerly VC-backed | Boston, MA | 0000 | 000000&0 | ||
| 000000 | Formerly VC-backed | Bothell, WA | 0000 | 00.000 | 000000&0 | 00.000 |
| 00000000 | Corporation | Austin, TX | 00 | 0000 | 00000000 | 0000 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
| 0000000 0000000000 | Corporate Backed or Acquired | Allschwil, Switzerland | 0000 | 00.000 | 00000000 | 00.000 |
Genentech Patents
Genentech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4148067-A1 | Method for the expression of an antibody-multimer-fusion | Pending | 08-Sep-2021 | 000000000 | 00 |
| US-20230049152-A1 | Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use | Pending | 14-Jul-2021 | 00000000000 | |
| US-20230048743-A1 | Structures for reducing antibody-lipase binding | Pending | 12-Jul-2021 | 000000000 | |
| US-20230014181-A1 | Culture system and methods for improved modeling of neurological conditions | Pending | 17-Jun-2021 | 000000000 | |
| US-20220380466-A1 | Methods for treatment of b cell proliferative disorders with anti-cd20/anti-cd3 bispecific antibodies | Pending | 01-Jun-2021 | A61P35/02 |
Genentech Executive Team (48)
Genentech Board Members (7)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alexander Hardy | Genentech | Chief Executive Officer & Board Member | 000 0000 |
Genentech Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Genentech Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Ignite500 Venture | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Kleiner Perkins | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Lubrizol | Corporation | Minority | 000 0000 | 000000 0 | |
| Mayfield (Private Equity) | Venture Capital | Minority | 000 0000 | 000000 0 |
Genentech Investments & Acquisitions (36)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000 (0 | 30-Jun-2022 | 000000000 | 00.00 | Buildings and Property | |
| 000000000 000 | 01-Aug-2021 | 0000000000 | Biotechnology | ||
| 00000000 0000 | 11-Jan-2021 | 00000 0000 | 00000 | Biotechnology | |
| 000 | 11-Sep-2019 | 0000000000 | Diagnostic Equipment | ||
| Parvus Therapeutics | 16-May-2019 | Corporate | Pharmaceuticals |
Genentech Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 000 | Diagnostic Equipment | Dallas, TX | 0000 |
Genentech Exits (20)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000000 | 16-Jul-2015 | 00000 00000 00 | 00000 | Completed |
|
| 0000000000000 0000 | 05-Aug-2014 | 00000 00000 00 | 000 | Completed |
|
| 0000000000000 0000 | 01-Jan-2012 | 00000 00000 00 | 0000 | Completed |
|
| 000000000 | 04-Feb-2009 | 00000 00000 00 | 000.00 | Completed |
|
| Tolerx | 30-Oct-2007 | Later Stage VC | 0000 | Completed |
|